. FIV MAP/peptide-specific T-cell proliferation and cytokine production of the PBMC from vaccinated cats at 3-6 weeks post-2nd vaccination. The results from CD4 + (A) and CD8 + (B) T-cell proliferation and the IL-2 (C) and IFNγ (D) production of the PBMC from the MAP-vaccinated cats are shown in response to the in vitro stimulation with MAP or FIV peptide. The vaccinated cats in Group 1a received concurrent subcutaneous plus intradermal (SC/ID) vaccinations with triple-MAP vaccine (grey bars) and evaluated for immune responses at 3 weeks post-2nd vaccination. Those in Groups 1b and 1c received either subcutaneous (SC) (dark blue bars) or intradermal (ID) (blue bars) vaccinations with quadruplicate-MAP vaccine, respectively and evaluated for immune responses at 6 weeks post-2nd vaccination. The identification codes of each vaccinated cat are shown in the top right inset of panel A. Each bar represents the average response from a single vaccinated cat after subtraction of the average value of the results from eight control cats, with the exception of the mitogen control. Only bars at ≥0.5% CFSE low threshold for CD4 + and CD8 + T-cell proliferation or at ≥50 SFU/10 6 PBMC threshold for IL-2 and IFNγ production are shown. BFA  DU4  DU5  DX1  DX5  OLL  HOC  RL2  RN4  RO1  RO7  RP4  RQ1  HOB  RL1  RL4  RN3  RO2  RP3 BFA  DU4  DU5  DX1  DX5  OLL  HOC  RL2  RN4  RO1  RO7  RP4  RQ1  HOB  RL1  RL4  RN3  RO2  RP3 Tables S1-S8   Table S1 . Selection of FIV p24 and RT peptide pool based on the number of responders Table S2 . Number of responders to individual peptides from the FIV peptide pools with the most feline or human CTL or CD8 + T-cell responders Table S3 . Challenge efficacy determined by virus load, proviral PCR, and FIV antibody detection Table S4 . Immunogenicity of HIV peptides counterpart to protective FIV peptides and FRT11 peptides Table S5 . Responder rate and average magnitude of the MAP/peptide responses by the unprotected cats from all vaccine groups Table S6 . Responder rate and average magnitude of the MAP/peptide responses by the protected cats from vaccine Group 1bc Table S7 . Comparing the responder rates between the selection study and MAP vaccine trial and between the post-2nd and post-3rd vaccinations Table S8 . Primers and probes for qRT-PCR Abbreviations: CD4 + T cell (CD4 T), CD8 + T cell (CD8 T), CD4 + CTL (CD4 CTL), CD8 + CTL (CD8 CTL), granzyme A (GrzA), granzyme B (GrzB), not done (n).
. FIV MAP/peptide-specific T-cell proliferation and cytokine production of the PBMC from vaccinated cats at 6 weeks post-3rd vaccination. The results from CD4 + (A) and CD8 + (B) T-cell proliferation and the IL-2 (C) and IFNγ (D) production of the PBMC from the MAPvaccinated cats are shown in response to the in vitro stimulation with MAP or FIV peptide. The vaccinated cats in Group 1a received concurrent subcutaneous plus intradermal (SC/ID) vaccinations with triple-MAP vaccine (grey bars), while those in Groups 1b and 1c received either subcutaneous (SC) (dark blue bars) or intradermal (ID) (blue bars) vaccinations with quadruplicate-MAP vaccine, respectively. The identification codes of each vaccinated cat are shown in the top right inset of panel A. Vaccinated cats in Group 1a were not tested (NT) for CD4 + and CD8 + T-cell proliferation to MAP4 and Fp9-3 as shown with (NT) in panels A and B. Each bar represents the average response from a single vaccinated cat after subtraction of the average value of the results from eight control cats, with the exception of the mitogen control. Only bars at ≥0.5% CFSE low threshold for CD4 + and CD8 + T-cell proliferation or at ≥50 SFU/10 6 PBMC threshold for IL-2 and IFNγ production are shown. Figure S3 . qRT-PCR analysis for the mRNA levels to the cytokines and the CTL-associated cytolysin/cytotoxins in the PBMC from vaccinated cats at 6 weeks post-3rd vaccination. The PBMC from four vaccinated cats each in Groups 1b (white bar) and 1c (black bar) and from four adjuvant control cats in Group 2c were stimulated for 14 h with either MAP, Fp9-3 peptide, or FIV peptide mixture. The FIV peptide mixtures consisted of FRT3-3/4 (FRT3-3, FRT3-4, and overlapping FRT3-3/FRT3-4 peptides), Fp14-3/4 (Fp14-3, Fp14-4, and overlapping Fp14-3/Fp14-4 peptides), and FRT7-1/2 (FRT7-1, FRT7-2, overlapping FRT7-1/FRT7-2 peptides). The mRNA levels of cytokines IL-2 and IFNγ, cytolysin perforin, cytotoxins GrzA and GrzB, and the surface cell marker CD107a molecule are shown as the relative expression of the average of four cats each from vaccine Groups 1b and 1c relative to the adjuvant control group. The results from the two vaccine groups are normalized with internal control GAPDH, and then represented as fold change over their media controls and the adjuvant control group. Those bars with more than twofold difference (above dotted line) are considered significant. Significant difference (p<0.05) between the two vaccine Groups 1b and 1c are shown with (*) above the Group 1c bar. Note that those bars without standard deviation bar are the results from one cat such as the GrzB results shown with responses from one cat each in both groups with exception of the response to FRT3-3/4 by Group 1c.
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FIV peptide pools for p24 (Fp#) and RT (FRT#) selected from previous studies using HIV + human subjects [17, 18] . Table S2 . Number of responders to individual peptides from the FIV peptide pools with the most feline or human CTL or CD8 + T-cell responders a Abbreviations: CD4 + (CD4 T) and CD8 + T cell (CD8 T), CD4 + CTL (CD4 CTL), CD8 + CTL (CD8 CTL), granzyme A (GrzA), granzyme B (GrzB), not done (n), tested also for CD107a (*). 
Fp3 Pool 9/18 (50) 9/18 (50) 7/12 (58) 0/6 (0) 0/27 (0) 0/27 (0) n n 2/21 (10) Fp3-1 1/6 (17) 1/6 (17) 1/6 (17) 1/6 (17) n n n n n Fp3-2 3/6 (50) 2/6 (33) 0/6 (0) 1/6 (17) n n n n n Fp3-3 2/6 (33) 2/6 (33) 0/6 (0) 0/6 (0) n n n n n Fp3-4 0/6 (0) 3/6 (50) 1/6 (17) 2/6 (33) n n n n n Fp4 Pool 11/18 (61) 8/18 (44) 1/12 (8) 2/6 (33) 0/27 (0) 0/27 (0) n n 2/21 (10) Fp4-1 2/6 (33) 2/6 (33) 0/6 (0) 2/6 (33) n n n n n Fp4-2 0/6 (0) 1/6 (17) 2/6 (33) 3/6 (50) n n n n n Fp4-3 0/6 (0) 1/6 (17) 3/6 (50) 1/6 (17) n n n n n ; not done (n). b Proviral and virus load in PBMC; virus load number of X represents 10 X /10 6 cells infected, with highest load of X=6 and undetectable load of X=0. c Group with sub-group identification code is group number followed by sub-group alphabet code; sub-group shown with cat identification code. d Sub-group 1a or Group 1a vaccination of (MAP2/±2v/3/±4/±5) means 1st vaccination with MAP2/3/4t and 2nd and 3rd vaccinations with MAP2/2v/3/5. e Sub-groups 1b plus 1c or Group 1bc with all three vaccinations with MAP2v/3/4/5. f Adjuvant supplemented with feline IL-12 for ID and concurrent SC/ID vaccinations. Bold value when CD8 + T-cell (CD8 T) proliferation or IL-2 production is ≥CD4 + T-cell (CD4 T) proliferation or ≥IFNγ production, respectively. Bold value when CD8 + T-cell (CD8 T) proliferation or IL-2 production is ≥CD4 + T-cell (CD4 T) proliferation or ≥IFNγ production, respectively. c Percent responder rate: the number of responders to the peptide divided by the total number of responders multiplied by 100. Bold value when CD8 + T-cell (CD8 T) proliferation is greater than or equal to CD4 + T cell (CD4 T) proliferation. 
